JP2022551270A - ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 - Google Patents
ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 Download PDFInfo
- Publication number
- JP2022551270A JP2022551270A JP2022520475A JP2022520475A JP2022551270A JP 2022551270 A JP2022551270 A JP 2022551270A JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022551270 A JP2022551270 A JP 2022551270A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- och
- independently
- ocf
- ch2ch3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113088A JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911069P | 2019-10-04 | 2019-10-04 | |
| US62/911,069 | 2019-10-04 | ||
| US202062991525P | 2020-03-18 | 2020-03-18 | |
| US62/991,525 | 2020-03-18 | ||
| PCT/US2020/054107 WO2021067836A1 (en) | 2019-10-04 | 2020-10-02 | Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113088A Division JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551270A true JP2022551270A (ja) | 2022-12-08 |
| JP2022551270A5 JP2022551270A5 (cg-RX-API-DMAC10.html) | 2024-03-28 |
Family
ID=72964859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520475A Pending JP2022551270A (ja) | 2019-10-04 | 2020-10-02 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
| JP2025113088A Pending JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113088A Pending JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11584728B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4038076A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022551270A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220078644A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114746430B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2020358970C1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3156499A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL291898B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021067836A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025164962A (ja) * | 2019-10-04 | 2025-10-31 | ステルス バイオセラピューティクス インコーポレイテッド | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022291142A1 (en) * | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| AU2024300048A1 (en) * | 2023-07-21 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| AU2024377199A1 (en) * | 2023-11-09 | 2026-05-21 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
| WO2026020091A1 (en) * | 2024-07-19 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations |
| WO2026050137A1 (en) * | 2024-08-26 | 2026-03-05 | Stealth Biotherapeutics Inc. | A combination therapy for the treatment of friedreich's ataxia |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008542389A (ja) * | 2005-06-01 | 2008-11-27 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬 |
| JP2009527567A (ja) * | 2006-02-22 | 2009-07-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| JP2016041772A (ja) * | 2010-08-06 | 2016-03-31 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
| JP2016515526A (ja) * | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2017087795A1 (en) * | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP2019504018A (ja) * | 2015-12-17 | 2019-02-14 | バイオエレクトロン テクノロジー コーポレイション | 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP2332534B1 (en) * | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (cg-RX-API-DMAC10.html) | 2009-08-26 | 2018-06-30 | ||
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) * | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| IL305687B2 (en) | 2017-12-15 | 2024-12-01 | Stealth Biotherapeutics Inc | Mitochondria-targeting peptides |
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
-
2020
- 2020-10-01 IL IL291898A patent/IL291898B1/en unknown
- 2020-10-02 IL IL328635A patent/IL328635A/en unknown
- 2020-10-02 JP JP2022520475A patent/JP2022551270A/ja active Pending
- 2020-10-02 US US17/062,339 patent/US11584728B2/en active Active
- 2020-10-02 CN CN202080084283.6A patent/CN114746430B/zh active Active
- 2020-10-02 EP EP20793924.0A patent/EP4038076A1/en active Pending
- 2020-10-02 CN CN202610035916.3A patent/CN121949079A/zh active Pending
- 2020-10-02 WO PCT/US2020/054107 patent/WO2021067836A1/en not_active Ceased
- 2020-10-02 CA CA3156499A patent/CA3156499A1/en active Pending
- 2020-10-02 AU AU2020358970A patent/AU2020358970C1/en active Active
- 2020-10-02 KR KR1020227014887A patent/KR20220078644A/ko active Pending
-
2022
- 2022-12-23 US US18/087,890 patent/US12049455B2/en active Active
-
2024
- 2024-07-02 US US18/761,854 patent/US20240400529A1/en active Pending
- 2024-07-02 US US18/761,782 patent/US20240368098A1/en active Pending
-
2025
- 2025-07-03 JP JP2025113088A patent/JP2025164962A/ja active Pending
-
2026
- 2026-05-02 AU AU2026203365A patent/AU2026203365A1/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008542389A (ja) * | 2005-06-01 | 2008-11-27 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬 |
| JP2009527567A (ja) * | 2006-02-22 | 2009-07-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| JP2016041772A (ja) * | 2010-08-06 | 2016-03-31 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| JP2016515526A (ja) * | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2017087795A1 (en) * | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
| JP2019504018A (ja) * | 2015-12-17 | 2019-02-14 | バイオエレクトロン テクノロジー コーポレイション | 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ1,4−ベンゾキノン誘導体 |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
Non-Patent Citations (2)
| Title |
|---|
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.20(3), JPN6024029503, 2010, pages 1063 - 1064, ISSN: 0005378595 * |
| EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 5, JPN6024029504, 1999, pages 1075 - 1084, ISSN: 0005378594 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025164962A (ja) * | 2019-10-04 | 2025-10-31 | ステルス バイオセラピューティクス インコーポレイテッド | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021067836A1 (en) | 2021-04-08 |
| AU2020358970B2 (en) | 2026-02-05 |
| US11584728B2 (en) | 2023-02-21 |
| KR20220078644A (ko) | 2022-06-10 |
| AU2020358970C1 (en) | 2026-08-06 |
| US20210206736A1 (en) | 2021-07-08 |
| IL328635A (en) | 2026-07-01 |
| CA3156499A1 (en) | 2021-04-08 |
| CN114746430A (zh) | 2022-07-12 |
| CN121949079A (zh) | 2026-05-01 |
| JP2025164962A (ja) | 2025-10-31 |
| US20240368098A1 (en) | 2024-11-07 |
| IL291898B1 (en) | 2026-06-01 |
| CN114746430B (zh) | 2026-01-30 |
| US20230303506A1 (en) | 2023-09-28 |
| EP4038076A1 (en) | 2022-08-10 |
| AU2026203365A1 (en) | 2026-07-23 |
| US12049455B2 (en) | 2024-07-30 |
| US20240400529A1 (en) | 2024-12-05 |
| IL291898A (en) | 2022-06-01 |
| AU2020358970A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020358970B2 (en) | Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases | |
| TWI689490B (zh) | 用於治療纖維化之經取代之芳族化合物及相關方法 | |
| EP3983384B1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
| JP6107650B2 (ja) | テトラヒドロカルボリン誘導体 | |
| US12037350B2 (en) | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | |
| CA3222132A1 (en) | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia | |
| WO2017124949A1 (zh) | 二氢黄酮衍生物、其制备方法和用途 | |
| HK40088188A (en) | Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia | |
| HK40088188B (en) | Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia | |
| CN118382435A (zh) | 12/15-脂氧合酶抑制剂 | |
| CN114920697A (zh) | 杂环基取代的茚满丙酰胺类化合物及其应用 | |
| CN120282779A (zh) | 4(rs)-4-f4-神经前列腺素衍生物(4-f4t-neurop)及其在治疗呼吸机导致的膈肌功能障碍和其他疾病中的用途 | |
| WO2005005433A1 (ja) | 高カルシウム血症および骨疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240314 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240726 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240729 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250127 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250303 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250703 |